Navigation Links
Sangamo BioSciences Announces Presentation At Regen Med Investor Day
Date:4/11/2013

RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will present at the 2013 Regen Med Investor Day to be held Wednesday, April 17, 2013 in New York City.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Burrill & Company, Maxim Group and Piper Jaffray , this flagship event features 16 of the regenerative medicine field's leading small- and mid-cap companies.

The following are specific details regarding Sangamo BioSciences' presentation at the conference:Event:

ARM's Regen Med Investor DayDate:

April 17, 2013Time:

2:45pm ESTLocation:

Harmonie Club, 4 East 60th Street, New York, NY 10022The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on both the Sangamo and ARM websites after the event.

The event also includes disease indication-focused discussions between key opinion leaders, top analysts and senior executives from the sector and keynote-style talks by Jeff Jonas , President of Shire Regenerative Medicine and Kieran Murphy , President and CEO, GE Healthcare Life Sciences.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://alliancerm.org/event/regen-med-investor-day for more information.

About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
2. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
6. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
7. Sangamo BioSciences Reports First Quarter 2012 Financial Results
8. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):